AsiDNA (a DNA Repair Inhibitor) Administered IntraVenously in Advanced Solid Tumors

PHASE1CompletedINTERVENTIONAL
Enrollment

33

Participants

Timeline

Start Date

April 5, 2018

Primary Completion Date

February 24, 2021

Study Completion Date

February 20, 2022

Conditions
Advanced Cancer
Interventions
DRUG

AsiDNA

"All patients will receive a loading dose of AsiDNA iv infusion (D1, D2, D3) followed by weekly iv administrations.~At cycle 1: Part B1: Carboplatin will be administered by a 1 hour IV infusion at D8, 1 hour after the end of AsiDNA infusion. Part B2: Carboplatin will be administered by a 1 hour IV infusion at D8, 1 hour after the end of AsiDNA infusion and Paclitaxel will be administered by a 1 hour IV infusion at D8, D15, D22 or 1 hour after the end of AsiDNA infusion for weekly administrations.~At each other cycle: AsiDNA will be administered on a weekly basis. Part B1: Carboplatin will be administered by a 1 hour IV infusion at D1, 1 hour after the end of AsiDNA infusion. Part B2; Carboplatin will be administered by a 1 hour IV infusion at D1, 1 hour after the end of AsiDNA infusion and Paclitaxel will be administered on a weekly basis by a 1 hour IV infusion.~Patients will continue study treatment until disease progression, unacceptable toxicity or patient's refusal to continue."

Trial Locations (5)

6000

Grand Hôpital de Charleroi, Charleroi

31059

Institut Claudius Regaud, Toulouse

69008

Centre Leon Berard, Lyon

75005

Institut Curie, Paris

B-1000

Institut Jules Bordet, Brussels

Sponsors
All Listed Sponsors
lead

Valerio Therapeutics

INDUSTRY

NCT03579628 - AsiDNA (a DNA Repair Inhibitor) Administered IntraVenously in Advanced Solid Tumors | Biotech Hunter | Biotech Hunter